Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
James E. Flynn Insider Profile
4 Followers
James E. Flynn, Possible Member of 10% Group, Ten Percent Owner at Vanda, holds 13.26M shares in AdaptHealth (Ticker: AHCO), holds 21.23M shares in Larimar Therapeutics (Ticker: LRMR), holds 2.67M shares in Acutus Medical (Ticker: AFIB). Most recently, James E. Flynn Sold ― shares of AdaptHealth on Mar 12, 2024 for an estimated value of 3.82M.
James E. Flynn Vanda (VNDA)Possible Member of 10% Group, Ten Percent Owner
Vanda (VNDA)
Possible Member of 10% Group, Ten Percent Owner
Ranked #75,783 out of 98,624 Corporate Insiders
Profitable Transactions
55 out of 123 Profitable Transactions
Average Return
-3.10%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that James E. Flynn holds in companies
Most Profitable Insider Trade
The most profitable trade made by James E. Flynn
James E. Flynn's Trading History
Vanda
Sep 26, 2016
Possible Member of 10% Group, Ten Percent Owner
Informative Sell
18.55M
$5.10M
XenoPort
Feb 23, 2016
―
Informative Buy
83.47K
$91.83M
Par Pharmaceutical Cos. Inc.
Aug 19, 2009
―
Informative Sell
4.24M
―
Larimar Therapeutics
Feb 16, 2024
Director, * Director by Deputization, Ten Percent Owner
Informative Buy
37.50M
$136.73M
AveXis Inc
―
―
―
―
Invuity
Dec 14, 2016
―
Informative Sell
1.15M
$13.86M
Societal CDMO
Jun 14, 2017
―
Informative Sell
706.23K
$2.28M
AdaptHealth
Mar 12, 2024
*Possible Member of 10% Group, Ten Percent Owner
Informative Sell
3.82M
$132.05M
Gyre Therapeutics
Mar 08, 2018
Possible Member of 10% Group, Ten Percent Owner
Informative Sell
2.19M
$19.05M
Q32 Bio
Jan 31, 2020
Possible Member of 10% Group, Ten Percent Owner
Informative Sell
8.02M
$114.53M
Mallinckrodt
May 10, 2018
―
Informative Sell
4.19M
$166.17K
Kiniksa Pharmaceuticals
May 31, 2018
*Possible member of 10% group, Ten Percent Owner
Uninformative Buy
―
$21.94M
Avadel Pharmaceuticals
Jun 25, 2018
*Possible member of 10% group, Ten Percent Owner
Informative Sell
683.06K
$65.44M
Xeris Pharmaceuticals
Feb 12, 2019
Possible Member of 10% Group, Ten Percent Owner
Informative Sell
109.20K
$4.12M
Constellation Pharmaceuticals
Jul 23, 2018
―
Uninformative Buy
―
$28.41M
Aerie Pharma
―
―
―
$59.34M
Arvinas Holding Company
Oct 01, 2018
Possible Member of a 10% Group, Ten Percent Owner
Uninformative Buy
―
$39.94M
Aclaris Therapeutics
Jul 01, 2019
Ten Percent Owner
Informative Sell
1.88M
$4.95M
Shockwave Medical
Mar 11, 2019
Possible Member of 10% Group, Ten Percent Owner
Uninformative Buy
―
$112.91M
Mirum Pharmaceuticals
Jun 08, 2022
* Possible Member of 10% Group, Ten Percent Owner
Informative Sell
962.26K
$79.36M
Cabaletta Bio
Oct 30, 2019
Possible Member of 10% Group, Ten Percent Owner
Uninformative Buy
―
$17.93M
Korro Bio
Oct 07, 2019
Possible Member of 10% Group, Ten Percent Owner
Uninformative Buy
―
$77.49M
Black Diamond Therapeutics
Feb 03, 2020
Possible Member of 10% Group, Ten Percent Owner
Uninformative Buy
―
$4.59M
Schrodinger
Feb 10, 2020
Possible Member of 10% Group, Ten Percent Owner
Uninformative Buy
―
$38.26M
Revolution Medicines
Feb 18, 2020
Possible Member of 10% Group, Ten Percent Owner
Uninformative Buy
―
$75.39M
Generation Bio
Jun 16, 2020
Possible Member of 10% Group, Ten Percent Owner
Uninformative Buy
―
$3.44M
Nkarta
Jul 14, 2020
Possible Member of 10% Group, Ten Percent Owner
Uninformative Buy
―
$16.62M
Annexon Biosciences
Jul 28, 2020
Possible Member of 10% Group, Ten Percent Owner
Uninformative Buy
―
$7.60M
Acutus Medical
Jun 20, 2023
Director, Director by deputization
Uninformative Buy
―
$443.09K
CalciMedica
Oct 01, 2020
*Possible Member of 10% Group, Ten Percent Owner
Uninformative Buy
―
$28.79M
Oncorus
Dec 30, 2022
―
Informative Sell
88.25K
$327.26K
Lumos Pharma
Jan 08, 2021
*Possible Member of 10% Group, Ten Percent Owner
Informative Sell
3.43M
$2.17M
Terns Pharmaceuticals
Feb 09, 2021
Possible Member of 10% Group, Ten Percent Owner
Uninformative Buy
―
$11.70M
Edgewise Therapeutics
Mar 30, 2021
Possible Member of 10% Group, Ten Percent Owner
Uninformative Buy
―
$63.60M
Werewolf Therapeutics
May 04, 2021
Possible Member of 10% Group, Ten Percent Owner
Uninformative Buy
―
$17.23M
CareMax
Nov 21, 2023
Director, Director by Deputization, Ten Percent Owner
Uninformative Buy
―
$49.37M
Nuvalent
Nov 07, 2022
Director, Director by deputization, Ten Percent Owner
Informative Buy
21.77M
$1.34B
Xilio Therapeutics
Oct 28, 2021
Possible Member of 10% Group, Ten Percent Owner
Uninformative Buy
―
$2.49M
Oncology Institute, Inc.
Nov 16, 2021
Possible Members of 10% Group, Ten Percent Owner
Uninformative Buy
―
$3.79M
PepGen Inc.
May 10, 2022
Possible Member of 10% Group, Ten Percent Owner
Uninformative Buy
―
$11.38M
Fractyl Health, Inc.
Feb 08, 2024
Possible Members of 10% Group, Ten Percent Owner
Uninformative Buy
―
$5.59M
BiomX
Mar 19, 2024
Director, *Director by Deputization, Ten Percent Owner
Uninformative Buy
―
$2.14M
Ehealth
Apr 27, 2017
Possible Members of 10% Group, Ten Percent Owner
Informative Sell
4.98M
$14.79M
AxoGen
Jul 21, 2016
Possible Member of 10% Group, Ten Percent Owner
Informative Sell
684.31K
$22.42M
Antares Pharma
Sep 30, 2015
―
Informative Sell
3.28M
$29.90M
Dicerna Pharma
Nov 25, 2014
―
Informative Sell
3.66M
$30.61M
Streamline Health Solutions
Dec 17, 2015
Possible Member of 10% Group, Ten Percent Owner
Informative Sell
486.71K
$602.04K
Steadymed
Mar 25, 2015
―
Uninformative Buy
―
$3.89M
Alimera
Dec 08, 2015
Possible Member of 10% Group, Ten Percent Owner
Informative Buy
817.58K
$3.90M
Invitae
Feb 19, 2015
Possible Member of 10% Group, Ten Percent Owner
Uninformative Buy
―
$532.27
Auxilium
Feb 02, 2015
―
Uninformative Sell
―
―
Cas Medical Systems
Jan 26, 2017
―
Informative Sell
928.48K
$0.00
Auspex Pharma
May 05, 2015
―
Uninformative Sell
―
―
Medicines Co
Apr 06, 2011
―
Informative Sell
6.98M
$261.11M
NxStage Medical
Dec 14, 2012
―
Informative Buy
―
$212.78M
Arena Pharma
―
―
―
$836.37M
Rigel
Jun 07, 2011
Possible Member of 10% Group, Ten Percent Owner
Informative Buy
5.20M
$3.55M
Fibrocell Science
Aug 18, 2010
―
Informative Sell
138.00K
$3.49M
Adverum Biotechnologies
Aug 05, 2014
Possible Members of 10% Group, Ten Percent Owner
Uninformative Buy
―
$5.76M
Loxo Oncology
Aug 06, 2014
―
Uninformative Buy
―
$69.49M
Protara Therapeutics
Dec 04, 2017
Director, *Director by Deputization
Informative Buy
193.47K
$3.58M
Trivascular Technologies
Apr 22, 2014
―
Uninformative Buy
―
$1.53M
Neurometrix
Dec 14, 2010
Possible Members of 10% Group, Ten Percent Owner
Informative Sell
169.13K
$3.47M
Cyclacel Pharmaceuticals
―
Possible Member of 10% Group, Ten Percent Owner
―
$1.33M
Neurogesx
Jul 15, 2009
―
Informative Sell
1.49M
$4.94K
Dynavax
―
Ten Percent Owner
―
$0.00
Hi-Tech Pharmacal Co., Inc.
Jul 21, 2010
―
Informative Buy
―
―
Salix
Sep 10, 2009
―
Informative Sell
13.43M
―
Somaxon Pharmaceuticals
Dec 20, 2012
―
Informative Buy
―
―
Talon Therapeutics Inc
Jul 18, 2013
―
Informative Sell
1.36M
―
List of latest transactions for each holding click on a transaction to see James E. Flynn's performance on stock
You May Also Like
James E. Flynn insider profile FAQ
What is the percentage of profitable transactions made by James E. Flynn?
The percentage of profitable transactions made by James E. Flynn is 45%.
What is the average return per transaction made by James E. Flynn?
The average return per transaction made by James E. Flynn is -3.10%.
What stocks does James E. Flynn hold?
James E. Flynn holds: VNDA, XNPT, PRX, LRMR, AVXS, IVTY, SCTL, AHCO, GYRE, QTTB, MNKKQ, KNSA, AVDL, XERS, CNST, AERI, ARVN, ACRS, SWAV, MIRM, CABA, KRRO, BDTX, SDGR, RVMD, GBIO, NKTX, ANNX, AFIB, CALC, ONCR, LUMO, TERN, EWTX, HOWL, CMAX, NUVL, XLO, TOI, PEPG, GUTS, PHGE, EHTH, AXGN, ATRS, DRNA, STRM, STDY, ALIM, NVTAQ, AUXL, CASM, ASPX, MDCO, NXTM, ARNA, RIGL, FCSC, ADVM, LOXO, TARA, TRIV, NURO, CYCC, NGSX, DVAX, HITK, SLXP, SOMX, TLON stocks.
What was James E. Flynn’s latest transaction?
James E. Flynn latest transaction was an Informative Sell of $3.82M.
What was James E. Flynn's most profitable transaction?
James E. Flynn’s most profitable transaction was an Informative Buy of SDGR stock on February 10, 2020. The return on the trade was 261.10%.
What is James E. Flynn's role in Vanda?
James E. Flynn's role in Vanda is Possible Member of 10% Group, Ten Percent Owner.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.